Ever wonder about all the non-cardiovascular diseases in #MI patients? Read this amazing paper on temporal trends on non-CV disease in MI patients through 17 years by @DanielMolager and @tsg_sehested in @JACCJournals. #CardioTwitter #NonCardiotwitter

Many relevant findings from PhD student @kasperbengtsen in his national study on risk factors associated with early and late S. aureus bacteraemia in CIED pts presented at #ESCCongress 🫀🧫 Congratulations on the hard work!👏👏 #ESC2023 #DCS_ESC23

Our new study demonstrates higher risk of MACE in ppl achieving initial remission of T2D. More attention to RF management with statins and RASi seems needed in lifestyle-treated individuals without glucose-lowering therapy. @CardiologyZuh @ARuwald @bochrajamal

Beyond glucose control, the opportunity for risk factor management in PPL with new #T2D often remains unfulfilled leading to higher rates of #heartdisease #CVD @Filip_Knop @DiabetologiaJnl https://t.co/HF2sKXHh7E

🔁 RT if you think 🇩🇰 @Mads__Pedersen is the Super-combative of the #TDF2023! 🔁 RT si vous pensez que 🇩🇰 @Mads__Pedersen est le Super-combatif du #TDF2023 !

What is the association between #frailty and time in hospital following #TAVR? Find out in @JAHA_AHA Frail patients have an⬆️risk of death & complications. For these patients, life-expectancy is limited and time in hospital is central for quality of life, yet data remain sparse

In this @TheLancet sdy @MariamElmegaard et al found that in 77,745 ptts w first time SGLT2-is and 56,037 GLP1-RAs the risk of discontinuing was 56% and 45%, respectively, w a decreased risk over the sdy-period https://t.co/zJWKje8tpy #Cardiotwitter @cardiology @diabetes

Data on all Danish first-time users of SGLT2is and GLP1-RAs from 2013 to 2021 show that ~50% discontinued therapy within five years, but a quarter of these reinitiated therapy during the following year. Discontinuation rates decreasing with time. https://t.co/DRY2zdHmYC

🧵 In our recent #Cochrane Review, we look at the impact of using #ActivePlacebo control versus standard placebo in randomised drug trials. https://t.co/7VwTOSRKxF #Blinding #Unblinding #Placebo #Bias @cochranemthds @AsgerPaludan @ChrisPaWer 1/10

In this sdy, @cnsolli et al. found that 1 dose of amoxicillin/clavulanic acid 500/125 mg or clindamycin 600 mg within 30-120 min. prior to hemodialysis was sufficient to maintain prophylactic plasma concentrations throughout the whole duration. 🦠+💊=💀 https://t.co/aDwPK1zhfa

Just out in @ESC_journals: Simple CHD💔patients faced ⬆️ lifetime risk of comorbidity i.a. #AF #mi #stroke & #heartfailure compared w controls, manifested in ⬆️ age 👴🏼🧓🏼. https://t.co/fN7ikB6Jt9 #ACHD #CVD #cardiotwitter @escardio @Hjerteforening @CopCard @ehj_ed

Improved outcomes after MI over time 📈 2️⃣0️⃣0️⃣0️⃣🆚2️⃣0️⃣1️⃣7️⃣ ☠️Mortality, 18.6% to 12.5% 💔Recurrent MI, 7.5% to 5.5% 🩸Bleeding, 3.9% to 2.7% Mortality was as low as 2.6% in 2015–17 for pts <60 years 👀 https://t.co/VW26roGqju #CardioTwitter #Cardiology

Long-term mortality, cardiovascular events, and bleeding in stable patients 1 year after myocardial infarction: a Danish nationwide study @escardio @ESC_Journals #CardioTwitter #EHJ #myocardialinfarction https://t.co/8QqhgkvZY4

Important contribution to the growing field of cardio-oncology. How does cancer type & status impact the prognosis of ACS? What is the cause of death? How are they managed? All important questions addressed by @NinaNouhravesh Find out below! https://t.co/AhLqMSd7fS

Cardiovascular disease was the leading cause of death in pts w active- and non-active cancers 🦀 Sdy from @NinaNouhravesh et al in @AmericanHeartJ 👇 https://t.co/DIw8XsTZKv

In this @ESC_Journals #QCCO sdy @PaulineRavn et al found decreasing ⬇️ risk of recurrent #myocardial_infarction, first-time admission 🏥 for #heartfailure and all-cause mortality 💀 in patients with a first-time myocardial infarction 🔗 https://t.co/P5nTXbdRRF

In this #EHJQCCO sdy @DanielMolager et al found influenza vaccine 💉 uptake is suboptimal among ptts w CVD, even w free-of-charge vaccinations 🧬 Vaccine uptake was particularly low among young patients 👦🏼👧🏾🧒🏽 🔗 https://t.co/yzwuDgCozd #cardiotwitter #Cardiology

This @IJCardio sdy by @cnsolli found that pts w/ myeloproliferative neoplasms in a DK cohort had ⬆️frequency of aortic valve and severe coronary artery calcifications than general pts. https://t.co/0wYP8DKrWH #cardiotwitter #atherosclerosis #dkforsk #hematology #mpn #mpnsm

In this @AnnalsofIM sdy @AndersHolt6 et al found that from 2000 to 2018, the use of PDE5 inhibitors🍆 increased 2️⃣0️⃣-fold among ptts with IHD who were taking nitrates No significant increased 🛑of CV events were found in these ptts 🔗 https://t.co/aOJT4bhfS4 #CardioTwitter

2 of our MDs @AnneSchjerning & @tsg_sehested have contributed to this paper by @DanielMolager et al in @ATHjournal who showed 1st time AMI has ⬇️ from 2005-2021 in DK in both sexes + all ages - most in elderly ≥ 70 yrs. 🫀 To continuous improvement!🥳 https://t.co/182n8GVX6Y